Patents by Inventor John Paul Kilburn

John Paul Kilburn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of the NMDA receptor
    Patent number: 11466027
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20220213117
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: January 25, 2022
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • Prodrugs of modulators of the NMDA receptor
    Patent number: 11358971
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: June 14, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20210047342
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: June 30, 2020
    Publication date: February 18, 2021
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20210002292
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: June 30, 2020
    Publication date: January 7, 2021
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION
    Publication number: 20200054630
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of depression.
    Type: Application
    Filed: February 25, 2019
    Publication date: February 20, 2020
    Inventors: JOHN PAUL KILBURN, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • CYCLIC AMINES
    Publication number: 20190307766
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Application
    Filed: October 10, 2018
    Publication date: October 10, 2019
    Inventors: JOHN PAUL KILBURN, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Benzamides-containing compounds and their use in the treatment of epilepsy
    Patent number: 10238654
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 26, 2019
    Assignee: MINDIMMUNE THERAPEUTICS, INC.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Cyclic amines
    Patent number: 10124010
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 13, 2018
    Assignee: MindImmune Therapeutics, Inc.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • INHIBITOR OF THE P2X7 RECEPTOR
    Publication number: 20180319786
    Abstract: The present invention provides (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2-(pyrimidin-2-yl)-4-(trifluoro-methyl)thiazole-5-carboxamide as P2X7 inhibitor, its use as a medicament, and a convenient enantiomeric synthesis protocol for the preparation of (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2-(pyrimidin-2-yl)-4-(trifluoromethyl)thiazole-5-carboxamide.
    Type: Application
    Filed: November 1, 2016
    Publication date: November 8, 2018
    Inventors: John Paul KILBURN, Allen T. HOPPER, Martin JUHL
  • CYCLIC AMINES
    Publication number: 20180177793
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Application
    Filed: March 19, 2018
    Publication date: June 28, 2018
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Cyclic amines
    Patent number: 9861639
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: January 9, 2018
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Quinoline derivatives as PDE10A enzyme inhibitors
    Patent number: 9801878
    Abstract: The present invention provides quinoline derivatives of formula I that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for PDE10A over other PDE subtypes. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: October 31, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Jacob Nielsen, Ask Püschl, John Paul Kilburn, Morten Langgård
  • Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy
    Publication number: 20170202836
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors
    Patent number: 9669029
    Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 6, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Ask Püschl, Jacob Nielsen, Jan Kehler, John Paul Kilburn, Mauro Marigo, Morten Langgård
  • Benzamide-containing compounds and their use in the treatment of pain
    Patent number: 9649308
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of pain.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: May 16, 2017
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Cyclic Amines
    Publication number: 20170128460
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Application
    Filed: January 25, 2017
    Publication date: May 11, 2017
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Substituted imidazoles as PDE10A inhibitors
    Patent number: 9592230
    Abstract: This invention is directed to phenylimidazole derivatives having the formula I: wherein HET is an optionally substituted heteroaromatic group; -L- is selected from the group consisting of —CH2—CH2—, —S—CH2—, —CH2—S— and —CH?CH—, R1 is selected from the group consisting of H, C1-C6 alkyl; C1-C6 alkyl(C3-C8)cycloalkyl; C1-C6 hydroxyalkyl, CH2CN, CH2C(O)NH2, C1-C6 arylalkyl, and C1-C6 alkyl-heterocycloalkyl, and R2, R3, R4, R5 and R6 are selected individually from the group consisting of H, C1-C6 alkoxy and halogen, or pharmaceutically acceptable acid addition salts thereof, which are PDE10A enzyme inhibitors useful in the treatment of psychiatric disorders and drug addiction.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 14, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Andreas Ritzen, Morten Langgard, Jan Kehler, Jacob Nielsen, John Paul Kilburn, Mohamed M. Farah
  • Cyclic amines
    Patent number: 9593105
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: March 14, 2017
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Cyclic Amines
    Publication number: 20170008898
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang